๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Endeavor II Three-Year Clinical Results: A Randomised, Double-Blind, Multicentre Trial of the Endeavor Zotarolimus-Eluting Stent for Treatment of Native Coronary Arteries

โœ Scribed by I. Meredith; John Ormiston; W. Wijns; J. Fajadet; R. Kuntz

Book ID
119254552
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
84 KB
Volume
16
Category
Article
ISSN
1443-9506

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

The Relation Between Clinical Features,
The Relation Between Clinical Features, Angiographic Findings, and the Target Lesion Revascularization Rate in Patients Receiving the Endeavor Zotarolimus-Eluting Stent for Treatment of Native Coronary Artery Disease: An Analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III
โœ Rajendra H. Mehta; Martin B. Leon; Michael H. Sketch Jr ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 398 KB
Late-Term Clinical Outcomes With Zotarol
Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
โœ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› American College of Cardiology ๐ŸŒ English โš– 704 KB
Long-Term Clinical and Economic Analysis
Long-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent: 4-Year Results From the ENDEAVOR II Trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions)
โœ Eric L. Eisenstein; William Wijns; Jean Fajadet; Laura Mauri; Rex Edwards; Patri ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› American College of Cardiology ๐ŸŒ English โš– 364 KB